1
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
Condition(s):HER2-Negative Breast CancerLast Updated:September 12, 2019Not yet recruiting
Pembrolizumab: 1127 Clinical Trials, Page 1 of 12
Hide Studies Not Open or Pending
2
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Condition(s):Stage IV Melanoma; Stage III Melanoma; Advanced MelanomaLast Updated:June 27, 2019Recruiting
3
Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Condition(s):Small Cell Lung CancerLast Updated:June 5, 2018Completed
4
Trial of Pembrolizumab in Cancer of Unknown Primary
Condition(s):Cancer of Unknown Primary SiteLast Updated:February 28, 2019Recruiting
5
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
Condition(s):Immunotherapy With Pembrolizumab for Nasopharyngeal Carcinoma PatientsLast Updated:May 31, 2018Not yet recruiting
6
Pembrolizumab-PET Imaging
Condition(s):Melanoma; Non-small Cell Lung CancerLast Updated:October 1, 2019Active, not recruiting
7
Pembrolizumab in Refractory Advanced Esophageal Cancer
Condition(s):Esophageal Cancer; Squamous Cell Esophagus Cancer; Adenocarcinoma EsophagusLast Updated:May 16, 2019Active, not recruiting
8
Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab
Condition(s):Transitional Cell Carcinoma of the Bladder; BiomarkersLast Updated:February 7, 2019Recruiting
9
Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen
Condition(s):SCCHNLast Updated:July 29, 2019Recruiting
10
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
Condition(s):Diffuse Large B Cell Lymphoma; LymphomaLast Updated:October 7, 2019Recruiting
11
89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer
Condition(s):Non Small Cell Lung CancerLast Updated:August 14, 2017Active, not recruiting
12
Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
Condition(s):Thymoma; Thymic CancerLast Updated:December 21, 2018Recruiting
13
Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning
Condition(s):Prostate CancerLast Updated:July 5, 2019Not yet recruiting
14
Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
Condition(s):Mycosis Fungoides/Sezary SyndromeLast Updated:October 7, 2019Not yet recruiting
15
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
Condition(s):Breast CancerLast Updated:February 14, 2019Recruiting
16
A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery
Condition(s):OsteosarcomaLast Updated:January 22, 2019Active, not recruiting
17
Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
Condition(s):Breast CancerLast Updated:May 8, 2019Recruiting
18
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Condition(s):Classical Hodgkin LymphomaLast Updated:February 24, 2019Terminated
19
Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
Condition(s):Liver Neoplasm Malignant Primary; Cholangiocarcinoma; Combinational Immunotherapy; BiomarkerLast Updated:July 12, 2019Recruiting
20
Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients
Condition(s):Stage IIIA Non-small Cell Lung CancerLast Updated:February 14, 2017Not yet recruiting
21
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Condition(s):Melanoma Recurrent; Malignant Melanoma; MelanomaLast Updated:September 26, 2017Completed
22
MRx0518 and Pembrolizumab Combination Study
Condition(s):Oncology; Solid Tumor; Non Small Cell Lung Cancer; Renal Cell Carcinoma; Melanoma; Bladder CancerLast Updated:October 28, 2019Recruiting
23
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
Condition(s):Castration-resistant Prostate CancerLast Updated:December 21, 2018Recruiting
24
Pembrolizumab in Refractory Metastatic Anal Cancer
Condition(s):Anal CancerLast Updated:July 23, 2019Recruiting
25
Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes
Condition(s):Breast CancerLast Updated:April 17, 2019Active, not recruiting
26
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Condition(s):Advanced CholangiocarcinomaLast Updated:May 16, 2019Terminated
27
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Condition(s):Melanoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck; Gastrointestinal Stromal Tumor (GIST); Ovarian CancerLast Updated:September 18, 2019Terminated
28
Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
Condition(s):Non Small Cell Lung CancerLast Updated:December 6, 2018Recruiting
29
Pembrolizumab as Neoadjuvant Treatment in HCC
Condition(s):Hepatocellular CarcinomaLast Updated:November 8, 2017Not yet recruiting
30
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC
Condition(s):Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell CarcinomaLast Updated:July 5, 2019Recruiting
31
Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
Condition(s):Squamous Cell Carcinoma of the Head and NeckLast Updated:December 12, 2018Terminated
32
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
Condition(s):Neuroendocrine TumorsLast Updated:September 26, 2019Active, not recruiting
33
Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)
Condition(s):Metastatic Melanoma Naive to Immune Therapy in Metastatic SettingLast Updated:August 30, 2018Recruiting
34
Neoadjuvant Pembrolizumab
Condition(s):Non-small Cell Lung CarcinomaLast Updated:February 12, 2019Active, not recruiting
35
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Condition(s):UC (Urothelial Cancer)Last Updated:August 14, 2019Active, not recruiting
36
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
Condition(s):MelanomaLast Updated:October 3, 2019Recruiting
37
Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer
Condition(s):Endometrial Cancer; Uterine CancerLast Updated:September 30, 2019Suspended
38
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
Condition(s):Estrogen Receptor Negative; HER2/Neu Negative; Metastatic Breast Cancer; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Triple Negative Breast CancerLast Updated:April 24, 2019Withdrawn
39
Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC
Condition(s):Lung CancerLast Updated:October 25, 2019Recruiting
40
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
Condition(s):Carcinoma, Non-Small-Cell LungLast Updated:July 8, 2019Active, not recruiting
41
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Condition(s):UC (Urothelial Cancer)Last Updated:August 27, 2019Active, not recruiting
42
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
Condition(s):Locally Advanced or Metastatic Solid TumorsLast Updated:April 5, 2018Completed
43
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
Condition(s):Classical Hodgkin Lymphoma; B-cell Non-Hodgkin Lymphoma; Acute Myeloid Leukemia; Myelodysplastic SyndromesLast Updated:October 7, 2019Recruiting
44
Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
Condition(s):Primary Liver CarcinomaLast Updated:June 7, 2019Recruiting
45
Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Condition(s):Bladder CancerLast Updated:June 26, 2017Terminated
46
A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
Condition(s):Malignant Peripheral Nerve Sheath Tumour (MPNST)Last Updated:March 12, 2019Active, not recruiting
47
Lenvatinib and Pembrolizumab Simultaneous Combination Study
Condition(s):Advanced Gastric CancerLast Updated:July 31, 2019Active, not recruiting
48
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
Condition(s):Gastric Cancer; Stomach Cancer; Esophageal CancerLast Updated:June 12, 2019Active, not recruiting
49
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Condition(s):Solid Tumor, AdultLast Updated:September 19, 2019Recruiting
50
Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
Condition(s):Small Cell Lung Cancer Extensive StageLast Updated:May 15, 2018Recruiting
51
Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
Condition(s):Hepatocellular CarcinomaLast Updated:May 17, 2019Recruiting
52
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Condition(s):High Grade MeningiomaLast Updated:August 13, 2019Recruiting
53
Combination of Pembrolizumab With Chemoradiation for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Condition(s):Esophageal Squamous Cell CarcinomaLast Updated:February 12, 2019Recruiting
54
Pembrolizumab (MK-3475) in MM Patients With Residual Disease
Condition(s):Multiple MyelomaLast Updated:December 10, 2018Active, not recruiting
55
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
Condition(s):Breast CancerLast Updated:July 26, 2019Recruiting
56
Pembrolizumab in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing (‘MUTATION2′)
Condition(s):Metastatic Breast CancerLast Updated:February 7, 2019Not yet recruiting
57
Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)
Condition(s):Carcinoma of Unknown PrimaryLast Updated:January 10, 2019Recruiting
58
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
Condition(s):Lung Cancer Metastatic; NSCLC Stage IV; Adenocarcinoma of LungLast Updated:April 2, 2019Recruiting
59
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Condition(s):Diffuse Large B Cell LymphomaLast Updated:March 11, 2019Not yet recruiting
60
A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)
Condition(s):Advanced MelanomaLast Updated:July 31, 2017Withdrawn
61
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
Condition(s):Triple Negative Breast Cancer; Inflammatory Breast Cancer Stage IVLast Updated:April 2, 2019Completed
62
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
Condition(s):Stage I Bladder Cancer AJCC v8; Stage II Bladder Cancer AJCC v8; Stage III Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8; Stage IIIB Bladder Cancer AJCC v8Last Updated:October 10, 2019Active, not recruiting
63
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Condition(s):Unresectable Malignant Neoplasm; Melanoma; Metastatic Melanoma; Stage IV Melanoma; Stage III MelanomaLast Updated:June 3, 2019Completed
64
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Condition(s):Childhood Solid Tumor; Childhood Lymphoma; Relapsed Cancer; Refractory Cancer; Adult Solid Tumor; Adult LymphomaLast Updated:October 8, 2019Recruiting
65
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
Condition(s):Squamous Cell Carcinoma of the Head and NeckLast Updated:April 18, 2019Withdrawn
66
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
Condition(s):Gynecologic Neoplasms; Epithelial Ovarian Cancer; Uterine Endometrial Cancer; Fallopian Tube Cancer; Peritoneal CancerLast Updated:May 24, 2019Active, not recruiting
67
A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Condition(s):Locally Advanced or Metastatic Urothelial Cell Carcinoma; Urinary Bladder Disease; Urological DiseasesLast Updated:September 19, 2019Active, not recruiting
68
Radiotherapy With Pembrolizumab in Metastatic HNSCC
Condition(s):Head and Neck Squamous Cell CarcinomaLast Updated:August 1, 2018Recruiting
69
Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
Condition(s):Non Small Cell Lung CancerLast Updated:February 3, 2019Recruiting
70
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)
Condition(s):Urinary Bladder Cancer, Muscle-invasiveLast Updated:October 30, 2019Recruiting
71
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Condition(s):Anaplastic Thyroid CancerLast Updated:October 10, 2019Recruiting
72
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
Condition(s):Penile Squamous Cell CarcinomaLast Updated:February 2, 2019Recruiting
73
Pembrolizumab for Newly Diagnosed Glioblastoma
Condition(s):Newly Diagnosed GlioblastomaLast Updated:April 1, 2019Not yet recruiting
74
Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
Condition(s):Hepatocellular CarcinomaLast Updated:October 14, 2019Recruiting
75
High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML
Condition(s):Acute Myeloid Leukemia, in RelapseLast Updated:September 2, 2019Active, not recruiting
76
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
Condition(s):CLL; B-cell Non Hodgkin LymphomaLast Updated:October 7, 2019Recruiting
77
Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2
Condition(s):Carcinoma, Non-Small-Cell LungLast Updated:April 12, 2019Active, not recruiting
78
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
Condition(s):Melanoma and Other Malignant Neoplasms of Skin; Metastatic MelanomaLast Updated:July 1, 2019Recruiting
79
Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas
Condition(s):Neuroendocrine Tumors; Neuroendocrine Carcinoma; Neuroendocrine CancerLast Updated:July 3, 2019Suspended
80
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Condition(s):Colorectal Neoplasms; Microsatellite InstabilityLast Updated:April 1, 2019Recruiting
81
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
Condition(s):Metastatic Renal Cell CarcinomaLast Updated:February 20, 2019Recruiting
82
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Condition(s):Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites; Malignant Neoplasms of Independent (Primary) Multiple Sites; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands; Malignant Neoplasms of Urinary TractLast Updated:September 4, 2019Recruiting
83
Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study
Condition(s):Muscle-invasive Bladder CancerLast Updated:February 4, 2019Not yet recruiting
84
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
Condition(s):Non-small Cell Lung Cancer AdenocarcinomaLast Updated:April 3, 2019Recruiting
85
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
Condition(s):Esophageal Squamous Cell CarcinomaLast Updated:November 4, 2018Recruiting
86
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
Condition(s):Colorectal Cancer; Metastatic CancerLast Updated:November 2, 2018Recruiting
87
Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer
Condition(s):Lung CancerLast Updated:June 19, 2018Active, not recruiting
88
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Condition(s):Recurrent Endometrial CancerLast Updated:October 1, 2019Recruiting
89
Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer
Condition(s):Breast Cancer; Chest Wall TumorLast Updated:May 29, 2019Not yet recruiting
90
Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
Condition(s):Recurrent Skin Carcinoma; Skin Squamous Cell CarcinomaLast Updated:October 17, 2019Active, not recruiting
91
Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
Condition(s):Merkel Cell CarcinomaLast Updated:October 30, 2019Recruiting
92
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)
Condition(s):Advanced MelanomaLast Updated:October 17, 2019Terminated
93
Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
Condition(s):Acral Lentiginous Melanoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Mucosal Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8Last Updated:October 28, 2019Recruiting
94
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Condition(s):Solid TumorsLast Updated:December 28, 2018Recruiting
95
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors
Condition(s):Non-Small Cell Lung Cancer; Urinary Bladder Neoplasms; Neoplasm Metastasis; MelanomaLast Updated:December 21, 2018Recruiting
96
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
Condition(s):Squamous Cell Cancer of Head and Neck; Triple Negative Breast Cancer; Epithelial Ovarian Cancer; Malignant Melanoma; Advanced Solid TumorsLast Updated:May 23, 2018Active, not recruiting
97
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Condition(s):Advanced HER2-negative Breast CancerLast Updated:October 7, 2019Active, not recruiting
98
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
Condition(s):MelanomaLast Updated:August 13, 2019Active, not recruiting
99
Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm
Condition(s):Lung Adenocarcinoma, Stage ILast Updated:November 29, 2017Not yet recruiting
100
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
Condition(s):Metastatic NSCLCLast Updated:January 10, 2019Recruiting